WO2016152907A1 - 胆管癌治療剤 - Google Patents
胆管癌治療剤 Download PDFInfo
- Publication number
- WO2016152907A1 WO2016152907A1 PCT/JP2016/059162 JP2016059162W WO2016152907A1 WO 2016152907 A1 WO2016152907 A1 WO 2016152907A1 JP 2016059162 W JP2016059162 W JP 2016059162W WO 2016152907 A1 WO2016152907 A1 WO 2016152907A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fgfr2
- cholangiocarcinoma
- acceptable salt
- bile duct
- duct cancer
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a therapeutic agent for cholangiocarcinoma containing a monocyclic pyridine derivative having a FGFR inhibitory action or a pharmacologically acceptable salt thereof.
- the compound represented by the formula (I) is 5-((2- (4- (1- (2-hydroxyethyl) piperidin-4-yl) benzamido) pyridin-4-yl) oxy) -6- (2 -Methoxyethoxy) -N-methyl-1H-indole-1-carboxamide.
- the compound represented by the formula (I) has an inhibitory action on fibroblast growth factor receptor (FGFR) 1, 2 and 3, and has an inhibitory action on cell growth of gastric cancer, lung cancer, bladder cancer and endometrial cancer. It has been reported to have (Patent Document 1).
- Bile duct cancer is known as a tumor with a poor prognosis, although its incidence is low.
- the main treatment for bile duct cancer is surgical removal of the bile duct, but in many cases cancer cells cannot be completely removed. In such a case, a combination administration of gemcitabine and cisplatin is performed after surgery (Non-patent Document 1).
- Celina Ang "Role of the fibroblast growth factor receptor axis incholangiocarcinoma", Journal of Gastroenterology and Hepatology, vol.30, p.1116-1122, 2015.
- the present inventors have conducted intensive studies and found that the compound represented by the formula (I) is effective for the treatment of cholangiocarcinoma, thereby completing the present invention.
- the present invention provides the following [1] to [12].
- the therapeutic agent according to [1] wherein the bile duct cancer is intrahepatic cholangiocarcinoma.
- a therapeutic agent that may be effective in treating cholangiocarcinoma.
- FIG. 2 is a schematic diagram showing the structure of the FGFR2-BICC1 type1 and type2 genes. It is a figure which shows the result of having analyzed the protein obtained by culture
- One embodiment of the present invention is a compound represented by formula (I): 5-((2- (4- (1- (2-hydroxyethyl) piperidin-4-yl) benzamido) pyridin-4-yl) oxy) A therapeutic agent for cholangiocarcinoma containing -6- (2-methoxyethoxy) -N-methyl-1H-indole-1-carboxamide or a pharmaceutically acceptable salt thereof.
- examples of the pharmacologically acceptable salt include a salt with an inorganic acid, a salt with an organic acid, or a salt with an acidic amino acid.
- the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like.
- salts with organic acids include acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, salts with carboxylic acids such as benzoic acid, methanesulfonic acid, ethanesulfonic acid And salts with sulfonic acids such as p-toluenesulfonic acid.
- salt with acidic amino acid include salts with aspartic acid, glutamic acid and the like.
- a preferred pharmacologically acceptable salt is succinate or maleate, and a more preferred salt is succinate.
- a pharmacologically acceptable salt a salt containing 1.5 times succinic acid on a mass basis (1.5 succinate) is particularly preferable with respect to the compound represented by formula (I).
- the compound represented by the formula (I) according to the present invention or a pharmacologically acceptable salt thereof can be produced, for example, by the method described in Patent Document 1.
- biliary duct is treated as being synonymous with biliary tract. That is, bile duct cancer means intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder duct cancer, gallbladder cancer or duodenal papilla cancer. Also included are those in which these cancers have spread to sites other than the bile duct.
- the therapeutic agent for cholangiocarcinoma of the present invention is particularly effective for intrahepatic cholangiocarcinoma.
- the therapeutic agent for cholangiocarcinoma of the present invention may be a solid preparation such as a tablet, granule, fine granule, powder or capsule, or a preparation for oral administration such as a liquid, jelly or syrup.
- the therapeutic agent for cholangiocarcinoma of the present invention may be a preparation for parenteral administration such as an injection, a suppository, an ointment, a cataplasm.
- the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof if necessary, an excipient, a binder, a disintegrant, a lubricant. Further, a pharmaceutically acceptable carrier such as a colorant may be added. Tablets, granules, powders, capsules and the like may be coated as necessary.
- an injection for intravenous administration, intramuscular administration, subcutaneous administration, intraperitoneal administration, etc.
- the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used.
- pharmaceutically acceptable carriers such as pH adjusters, buffers, suspending agents, solubilizers, antioxidants, preservatives (preservatives), and isotonic agents.
- injectables can be produced by conventional methods. Alternatively, it may be freeze-dried to obtain a freeze-dried preparation that is dissolved at the time of use.
- a base material is added to the compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
- a pharmaceutically acceptable carrier such as an agent, a pH adjuster, an antioxidant, a colorant and the like, and by a conventional method, for example, a transdermal absorption preparation (ointment, patch, etc.), eye drops, nasal drop A suppository, a suppository, etc. can be manufactured.
- the base material to be used for example, it is possible to use various raw materials usually used for pharmaceuticals, quasi drugs, cosmetics and the like.
- the therapeutic agent for cholangiocarcinoma of the present invention can be produced by the method described in the 16th revision Japanese Pharmacopoeia using the compound represented by the formula (I) or a pharmacologically acceptable salt thereof. .
- the dose of the compound represented by formula (I) or a pharmacologically acceptable salt thereof is the degree of symptoms, patient age, sex, body weight, sensitivity difference, administration method Depending on the administration time, the administration interval, the type of pharmaceutical preparation, etc., it can be appropriately selected.
- the dose of the compound represented by the formula (I) or a pharmacologically acceptable salt thereof is 100 ⁇ g / day to an adult (body weight 60 kg).
- the dose may be 10 g, preferably 500 ⁇ g to 10 g, more preferably 1 mg to 5 g.
- the therapeutic agent for cholangiocarcinoma of the present invention can be administered in 1 to 3 divided doses per day.
- a method for treating cholangiocarcinoma can be provided by administering to a patient a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof.
- the subject to be administered is preferably a cholangiocarcinoma patient, more preferably an intrahepatic cholangiocarcinoma patient, and particularly preferably a cholangiocarcinoma patient having a gene encoding FGFR2 fusion protein (FGFR fusion gene).
- the FGFR2 fusion gene means a gene in which the FGFR2 gene and a specific other gene are fused.
- FGFR2-BICC1 type 1 refers to a gene fused with FGFR2 at the 5 ′ end of the KHKH sequence of the BICC1 gene
- FGFR2-BICC1 type 2 refers to the SAM region (sterile (sterile) of the BICC1 gene.
- FGFR2-BICC1 type 1 encodes a peptide consisting of 1574 amino acids
- FGFR2-BICC1 type 2 encodes a peptide consisting of 835 amino acids (SEQ ID NO: 6).
- BICC1 type1 was also called BICC1 until BICC1 type2 was discovered.
- FGFR2-AHCYL1, FGFR2-BICC1 type1, FGFR2-BICC1 type2, FGFR2-TXLNA or FGFR2-KCTD1 is preferred
- FGFR2-BICC1 type FGFR1-TFT2-XCT2-RCTRD2-X are more preferred, and patients with FGFR2-BICC1 type 2 are particularly preferred.
- the diagnosis method for the presence or absence of the FGFR2 fusion gene may be a commonly used gene diagnosis method.
- FGFR2-BICC1 type 2 SEQ ID NO: 5
- FGFR2-TXLNA SEQ ID NO: 1
- FGFR2-KCTD1 SEQ ID NO: 3
- a nucleotide sequence encoding a FLAG epitope tag was ligated to the amino group side end of each obtained FGFR2 fusion gene cDNA according to the translation reading frame, and cloned into a pMXs retrovirus vector to prepare a retrovirus.
- the linked FGFR2 fusion gene is also referred to as “wild type FGFR2 fusion gene”.
- the peptide sequence of the FLAG epitope tag is H 2 N-DYKDDDDK-COOH (molecular weight: 1012 Da).
- the polynucleotide sequences of the cDNAs of FGFR2, TXLNA, and KCTD1 correspond to SEQ ID NOs: 7, 9, and 11, respectively, and the sequences of the peptides encoded by FGFR2, TXLNA, and KCTD1 are SEQ ID NOs: 8, 10, and 12, respectively.
- a retrovirus was prepared by further mutating two amino acids in the site encoding FGFR2 kinase in the wild-type FGFR2 fusion gene.
- the mutation means that tyrosine, which is the 568th residue, is substituted with phenylalanine (Y568F), and tyrosine, which is the 568th residue, is substituted with phenylalanine (Y569F).
- Y568F phenylalanine
- Y569F phenylalanine
- the gene obtained by adding the above mutation to the wild-type FGFR2 fusion gene is also referred to as “KD mutant FGFR2 fusion gene”.
- Each of these retroviruses is infected with a mouse immortal fibroblast cell line NIH3T3 cell, introduced with a wild type FGFR2 fusion gene or a KD mutant FGFR2 fusion gene, and a cell line that stably expresses the protein encoded by each.
- Test Example 1 Immunoblotanalysis First, a wild type FGFR2 fusion gene or a KD mutant FGFR2 fusion gene was introduced into the mouse fibroblast cell line NIH3T3 using a retrovirus, and the resulting cell line was cultured in a liquid medium. The cultured cell line was serum-starved and then treated with a medium containing an FGFR inhibitor before extracting the total protein.
- the protein encoded by FGFR2-BICC1 type2 the protein encoded by FGFR2-TXLNA
- FGFR2-KCTD1 are as shown in SEQ ID NOs: 6, 2, and 4, respectively.
- the resulting total protein was analyzed for the downstream signal of the fusion gene by performing Western blot analysis using various antibodies.
- apparatus WesternBreeze chemilumiscentimmunodetection kit (Lifetechnologies)
- FGFR inhibitors Store in BGJ398 (S2183, Selleck chemicals), 10mMDMSO solution PD173074 (S1264, Selleck chemicals), compound A stored in 10mMDMSO solution (stored in 20mM DMSO solution) antibody: FLAG (# 635691, Clontech Laboratories, Inc.) phospho FGFR-Y653 / 654 (# 3476, Cellsignaling technology Japan Ltd.) phospho AKT1-S473 (# 4060, Cell signalingtechnology Japan Ltd.) AKT-pan (# 4691, Cell signaling technology Japan Ltd.) phospho STAT3-Y705 (# 9145, Cell signalingtechnology Japan Ltd.) STAT3 (# 610189, Becton Dickinson and Company) phospho MAPK-T202
- FIG. 2 it was found that phosphorylation of the MAPK gene (activation of the MAPK gene) occurs depending on the FGFR2 kinase activity. That is, NIH3T3 cells into which the FGFR2 fusion gene was introduced had an anchorage-independent growth ability.
- Wild means a wild type FGFR2 fusion gene
- KD means a KD mutant FGFR2 fusion gene.
- the NIH3T3 cell line into which the FGFR2 fusion gene was introduced was added with an FGFR inhibitor (final concentration of FGFR inhibitor: 0.2 ⁇ M or 0.5 ⁇ M), and after extracting the total protein in the same manner, Western blot analysis was performed. went.
- BG means BGJ398,
- PD means PD173074, and
- E9 means Compound A.
- BG-0.2 means that BGJ398 was added to a final concentration of 0.2 ⁇ M.
- the total protein was similarly extracted from the NIH3T3 cell line into which the FGFR2 fusion gene was not introduced and the NIH3T3 cell line into which FGFR2-BICC1 type2, FGFR2-TXLNA or FGFR2-KCTD1 was introduced. 90 ⁇ g of extracted total protein was used to analyze the expressed protein using a PathScan® array.
- phosphorylated Akt pAkt-S473
- phosphorylated MAPK pMAPK-T202 / Y204
- phosphorylated S6 ribosomal protein pS6-S235 / 236) were detected.
- Test example 2 Colonyformation assay The effect of the FGFR inhibitor on the transformation ability of the FGFR2 fusion polypeptide was evaluated using the following apparatus. That is, the NIH3T3 cell line into which the FGFR2 fusion gene has been introduced is seeded in a soft agar medium (agar concentration in medium: 4 mg / mL), and an FGFR inhibitor is added to the medium (final concentration of FGFR inhibitor: 0.2 ⁇ M), the anchorage-independent colony forming ability was evaluated.
- CytoSelect 96-Well Cell Transformation Assay kit (CBA-130, CellBiolabs)
- FGFR inhibitors Store in BGJ398 (S2183, Selleck chemicals), 10mMDMSO solution PD173074 (S1264, Selleck chemicals), compound A stored in 10mMDMSO solution (stored in 20mM DMSO solution)
- BGJ398 or PD173074 was increased to a final concentration of 1.0 ⁇ M, the anchorage-independent growth was suppressed.
- PD means PD173074.
- Test Example 3 IC 50 Value Calculation by Colonyformation Assay Using D-MEM (Wako Pure Chemical Industries) medium containing 10% FBS and penicillin / streptomycin (Wako Pure Chemical Industries) in a 5% CO 2 incubator (37 ° C.) Various NIH3T3 cell lines introduced with the FGFR2 fusion gene were maintained in culture. 50 ⁇ L of D-MEM medium (SIGMA) containing 10% FBS and penicillin / streptomycin containing 0.66% agar medium (DIFCO Agar Noble, Nippon Becton Dickinson) in each well of a 96-well plate (Sumitomo Bakelite) added.
- SIGMA D-MEM medium
- DIFCO Agar Noble Nippon Becton Dickinson
- Test Example 4 Antitumor Effect in Subcutaneous Transplant Model Mouse (1) Preparation of Subcutaneous Transplant Model Mouse NIH3T3 cell line into which each FGFR2 fusion gene (FGFR2-BICC1 type2, FGFR2-KCTD1, FGFR2-TXLNA) was introduced was treated with 10% FBS. And cultured in a DMEM culture solution containing penicillin / streptomycin. D-PBS ( ⁇ ) (Wako Pure Chemical Industries, Ltd.) was added to the obtained culture solution so as to be 1 ⁇ 10 7 cells / mL to prepare cell suspensions.
- FGFR2 fusion gene FGFR2-BICC1 type2, FGFR2-KCTD1, FGFR2-TXLNA
- Tumor volume (mm 3 ) major axis (mm) ⁇ minor axis (mm) ⁇ minor axis (mm) / 2
- Preparation of Compound A Solution Compound A was dissolved in water for injection and stored under light-shielding conditions at 4 ° C. until immediately before administration. The dose of Compound A was adjusted to 6.25, 12.5, 25 and 50 mg / kg when administered to mice at a dose of 20 mL / kg.
- (3) Administration of drug solution Based on the tumor volume on the first day of administration, the mice were divided into groups so that the average values of the tumor volumes of each group were almost equal. The number of mice per group was 5.
- the compound A solution was orally administered once a day at a dose of 20 mL / kg.
- the solvent alone water for injection
- FGFR2-BICC1 type2 or FGFR2-KCTD1 transplant model mice were administered for 7 days
- FGFR2-TXLNA transplant model mice were administered for 11 days.
- the body weights of the mice in the control group and the compound A administration group were measured. The weight ratio of the last day to the weight of the first day (relative body weight: RBW) was calculated.
Abstract
Description
[1]式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬剤学的に許容される塩を含有する胆管癌治療剤。
[2]胆管癌が肝内胆管癌である、[1]に記載の治療剤。
[3]式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬剤学的に許容される塩を有効成分として含有する、胆管癌治療用の医薬組成物。
[4]胆管癌が肝内胆管癌である、[3]に記載の医薬組成物。
[5]式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬剤学的に許容される塩の薬理学的有効量を患者に投与して、胆管癌を治療する方法。
[6]前記患者は、投与前にFGFR2融合タンパクをコードする遺伝子を有することが確認されている、[5]に記載の方法。
[7]前記FGFR2融合タンパクをコードする遺伝子が、FGFR2-AHCYL1、FGFR2-BICC1 type1、FGFR2-BICC1 type2、FGFR2-TXLNA、またはFGFR2-KCTD1である、[6]に記載の方法。
[8]胆管癌が肝内胆管癌である、[5]~[7]のいずれかに記載の方法。
[9]胆管癌治療のための、式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬剤学的に許容される塩。
[10]胆管癌が肝内胆管癌である、[9]に記載の化合物またはその薬剤学的に許容される塩。
[11]胆管癌治療剤の製造のための、式(I)で表される5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミドまたはその薬剤学的に許容される塩の使用。
[12]胆管癌が肝内胆管癌である、[11]に記載の使用。
5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミド 1.5コハク酸塩(以下、化合物Aと表記する場合がある)の製造
5-((2-(4-(1-(2-ヒドロキシエチル)ピペリジン-4-イル)ベンズアミド)ピリジン-4-イル)オキシ)-6-(2-メトキシエトキシ)-N-メチル-1H-インドール-1-カルボキサミド 2.93gをナスフラスコに量り取り、60mLのエタノールを加え、攪拌しながらオイルバスで70℃に加熱し、溶解させた。コハク酸(1.23g)を加えた後、オイルバスの加熱を止め、徐冷した。室温で約2時間攪拌した後、さらに5℃で1時間攪拌した。生じた固体をろ取して、化合物Aを得た(3.70g)。
1H-NMR Spectrum(600MHz, CD3OD) δ(ppm): 1.96-2.10 (4H, m), 2.52 (6H, s), 2.93 (1H, m), 2.96 (3H, s),3.01 (2H, m), 3.16 (2H, t, J=5.4 Hz), 3.22 (3H, s), 3.56 (2H, t, J=4.7 Hz),3.61 (2H, m), 3.87 (2H, t, J=5.4 Hz), 4.14 (2H, t, J=4.6 Hz), 6.61 (1H, d, J=3.6Hz), 6.68 (1H, dd, J=5.8, 2.3 Hz), 7.37 (1H, s), 7.42 (2H, d, J=8.3 Hz), 7.58(1H, d, J=3.6 Hz), 7.73 (1H, d, J=2.2 Hz), 7.88 (2H, d, J=8.3 Hz), 8.08 (1H,s), 8.15 (1H, d, J=5.8 Hz).
13C-NMRSpectrum (100MHz, solid state) δ(ppm): 27.1, 28.3, 29.7, 34.8, 38.0, 41.3, 54.0, 57.3, 59.7, 60.9,72.1, 72.5, 103.3, 104.2, 108.5, 116.9, 126.9, 128.6, 134.5, 136.7, 140.7,149.4, 151.3, 155.1, 169.5, 170.1, 175.6, 179.9, 183.7.
胆道がん患者由来のがん組織より、3種のFGFR2融合遺伝子(FGFR2-BICC1 type2(配列番号5)、FGFR2-TXLNA(配列番号1)、FGFR2-KCTD1(配列番号3))のcDNAをそれぞれ調製した。得られた各FGFR2融合遺伝子cDNAのアミノ基側末端にFLAGエピトープタグをコードする塩基配列を翻訳の読み枠に合わせて連結し、pMXsレトロウイルスベクターにクローニングして、レトロウイルスを作製した。ここで、上記連結されたFGFR2融合遺伝子を「野生型FGFR2融合遺伝子」ともいう。なお、FLAGエピトープタグのペプチド配列は、H2N-DYKDDDDK-COOH(分子量:1012Da)である。
ここで、FGFR2、TXLNA及びKCTD1の各cDNAのポリヌクレオチド配列は、それぞれ配列番号7、9、11に対応し、FGFR2、TXLNA及びKCTD1がコードするペプチドの配列は、それぞれ配列番号8、10、12に対応する。
cDNA cloning:
pMXs vector (CellBiolabs), Plat-Eretrovirus packaging cell (CellBiolabs)
まず、マウス線維芽細胞株NIH3T3にレトロウイルスを用いて、野生型FGFR2融合遺伝子またはKD変異型FGFR2融合遺伝子を導入し、得られた細胞株を液体培地で培養した。培養した細胞株を血清飢餓処理した後に、FGFR阻害剤を含有する培地で処理してから総タンパク質を抽出した。ここで、FGFR2-BICC1 type2がコードするタンパク、FGFR2-TXLNAがコードするタンパク、FGFR2-KCTD1がコードするタンパクは、それぞれ配列番号6、2、4に示すとおりである。
装置:
WesternBreeze chemilumiscentimmunodetection kit (Lifetechnologies)
FGFR阻害剤:
BGJ398 (S2183, Selleck chemicals), 10mMDMSO溶液で保管
PD173074 (S1264, Selleck chemicals), 10mMDMSO溶液で保管
化合物A (20mM DMSO溶液で保管)
抗体:
FLAG (#635691, Clontech Laboratories, Inc.)
phospho FGFR-Y653/654 (#3476, Cellsignaling technologyジャパン株式会社)
phospho AKT1-S473 (#4060, Cell signalingtechnologyジャパン株式会社)
AKT-pan (#4691, Cell signaling technologyジャパン株式会社)
phospho STAT3-Y705 (#9145, Cell signalingtechnologyジャパン株式会社)
STAT3 (#610189, Becton Dickinson andCompany)
phospho MAPK-T202/Y204 (#9106, Cellsignaling technologyジャパン株式会社)
MAPK (#4695, Cell signaling technologyジャパン株式会社)
beta-actin (#A5441, Sigma-Aldrich Co. LLC.)
抗体アレイ:
PathScan RTK signaling antibody array(Chemiluminescent Readout) (#7982, Cell signaling technologyジャパン株式会社)
以下の装置を用いて、FGFR2融合ポリペプチドの形質転換能に対するFGFR阻害剤の効果を評価した。すなわち、FGFR2融合遺伝子を導入したNIH3T3細胞株を、ソフトアガー培地(培地中のアガー濃度:4mg/mL)に播種し、当該培地中にFGFR阻害剤を添加して(FGFR阻害剤の最終濃度:0.2μM)、足場非依存性コロニー形成能を評価した。
装置:
CytoSelect 96-Well Cell TransformationAssay kit (CBA-130, CellBiolabs)
FGFR阻害剤:
BGJ398 (S2183, Selleck chemicals), 10mMDMSO溶液で保管
PD173074 (S1264, Selleck chemicals), 10mMDMSO溶液で保管
化合物A (20mM DMSO溶液で保管)
10%FBSおよびペニシリン/ストレプトマイシン(和光純薬工業)を含むD-MEM(和光純薬工業)培地を用い、5%CO2インキュベーター中(37℃)で、FGFR2融合遺伝子を導入した各種NIH3T3細胞株の培養維持をおこなった。96ウェルプレート(住友ベークライト)の各ウェルに、0.66%アガー培地(DIFCO Agar Noble、日本ベクトン ディッキンソン)を含むD-MEM培地(SIGMA)(10%FBS、ペニシリン/ストレプトマイシンを含む)を50μLずつ加えた。細胞数が4×104cells/mLとなるように調製した細胞懸濁液(FGFR2-TXLNA発現細胞の細胞数は8×104cells/mLとなるように調製された)と、0.66%アガー培地液を等量ずつ混ぜ、50μLずつ重層し4℃で30分程度冷やし固めた。プレートを室温に戻した後、0.66%アガー培地液をさらに50μLずつ重層した。10%FBSを含むDMEM培地にて希釈した化合物Aを、各ウェルに50μLずつ添加し、5%CO2インキュベーター中(37℃)で14日間培養した。細胞数測定キット(Cell Counting Kit-8、同仁化学研究所)10μLを各ウェルに添加し、5%CO2インキュベーター中(37℃)で1-2時間培養し発色させた。マルチラベルリーダー(ARVO、パーキンエルマー社)により450nmの吸光度を測定した。化合物Aを添加していない場合の吸光度を100%、細胞が存在していないウェルの吸光度を0%として、化合物A存在下での吸光度率を求めた。細胞増殖を50%阻害するのに必要な化合物Aの濃度(IC50値)を求め、表1に示した。
(1)皮下移植モデルマウスの作製
各FGFR2融合遺伝子(FGFR2-BICC1 type2、FGFR2-KCTD1、FGFR2-TXLNA)を導入したNIH3T3細胞株を、10%FBS、ペニシリン/ストレプトマイシンを含むDMEM培養液で培養した。
1×107cells/mLとなるように、得られた培養液にD-PBS(-)(和光純薬工業)を加えて、細胞懸濁液をそれぞれ調製した。
これらの細胞懸濁液を、7週齢のヌードマウス(系統:BALB/cAJcl-nu/nu、雌、日本クレア株式会社)の右脇腹皮下部に、100μLの投与量で移植し、FGFR2-BICC1 type2移植モデルマウス、FGFR2-KCTD1移植モデルマウスおよびFGFR2-TXLNA移植モデルマウスを作製した。移植から6日後に、デジタルノギス(商品名:デジマチックTMキャリパ、株式会社ミツトヨ)を用いて、腫瘍の短径、長径を計測した。腫瘍の短径および長径に基づき、以下の計算式で腫瘍体積を算出した。
腫瘍体積(mm3)=長径(mm)×短径(mm)×短径(mm)/2
(2)化合物A溶液の調製
化合物Aを注射用水にて溶解し、投与直前まで4℃にて遮光条件で保存した。マウスに20mL/kgの用量で投与した場合に、化合物Aの投与量が6.25、12.5、25および50mg/kgとなるように調製した。
(3)薬液の投与
投与初日の腫瘍体積に基づき、各群の腫瘍体積の平均値がほぼ等しくなるように、マウスを群分けした。1群あたりのマウスの数は5匹とした。化合物A投与群のマウスには、化合物A溶液を20mL/kgの投与量で、1日1回連続経口投与した。一方、コントロール群のマウスには、溶媒のみ(注射用水)を同様に投与した。FGFR2-BICC1 type2またはFGFR2-KCTD1移植モデルマウスには7日間、FGFR2-TXLNA移植モデルマウスには11日間、投与を行った。
投与初日と投与最終日に、コントロール群、化合物A投与群それぞれのマウスの体重を測定した。初日の体重に対する最終日の体重比(relative body weight:RBW)を算出した。化合物A投与群のRBW/コントロール群のRBWが、0.9以上だった場合に、安全な投与量と判定した。これに該当する投与量は、6.25、12.5、25および50mg/kgであった。
また、投与最終日に、腫瘍体積を測定した。コントロール群のマウスの腫瘍体積に対する化合物A投与群のマウスの腫瘍体積の割合(T/C)(%)を算出した。
Claims (12)
- 胆管癌が肝内胆管癌である、請求項1に記載の治療剤。
- 胆管癌が肝内胆管癌である、請求項3に記載の医薬組成物。
- 前記患者は、投与前にFGFR2融合タンパクをコードする遺伝子を有することが確認されていることを特徴とする、請求項5に記載の方法。
- FGFR2融合タンパクをコードする遺伝子が、FGFR2-AHCYL1、FGFR2-BICC1 type1、FGFR2-BICC1 type2、FGFR2-TXLNA、またはFGFR2-KCTD1である、請求項6に記載の方法。
- 胆管癌が肝内胆管癌である、請求項5~7のいずれか一項に記載の方法。
- 胆管癌が肝内胆管癌である、請求項9に記載の化合物またはその薬剤学的に許容される塩。
- 胆管癌が肝内胆管癌である、請求項11に記載の使用。
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017127135A RU2712222C2 (ru) | 2015-03-25 | 2016-03-23 | Терапевтическое средство против рака желчных протоков |
AU2016237222A AU2016237222B2 (en) | 2015-03-25 | 2016-03-23 | Therapeutic agent for bile duct cancer |
SG11201706143SA SG11201706143SA (en) | 2015-03-25 | 2016-03-23 | Therapeutic agent for bile duct cancer |
ES16768810T ES2887148T3 (es) | 2015-03-25 | 2016-03-23 | Agente terapéutico contra el cáncer de vías biliares |
US15/547,139 US20180015079A1 (en) | 2015-03-25 | 2016-03-23 | Therapeutic agent for bile duct cancer |
CN202210570963.XA CN114984013A (zh) | 2015-03-25 | 2016-03-23 | 胆管癌治疗剂 |
EP16768810.0A EP3275442B1 (en) | 2015-03-25 | 2016-03-23 | Therapeutic agent for bile duct cancer |
BR112017016392-6A BR112017016392B1 (pt) | 2015-03-25 | 2016-03-23 | Agente terapêutico para câncer do ducto biliar |
MX2017009892A MX2017009892A (es) | 2015-03-25 | 2016-03-23 | Agente terapeutico contra el colangiocarcinoma. |
KR1020177021185A KR102537152B1 (ko) | 2015-03-25 | 2016-03-23 | 담관암에 대한 치료제 |
CA2974937A CA2974937C (en) | 2015-03-25 | 2016-03-23 | Therapeutic agent for bile duct cancer |
JP2017508383A JP6503450B2 (ja) | 2015-03-25 | 2016-03-23 | 胆管癌治療剤 |
CN201680007472.7A CN107205996A (zh) | 2015-03-25 | 2016-03-23 | 胆管癌治疗剂 |
IL253701A IL253701B (en) | 2015-03-25 | 2017-07-27 | Medicinal material for bile duct cancer |
US16/225,772 US20190111043A1 (en) | 2015-03-25 | 2018-12-19 | Therapeutic agent for bile duct cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562138058P | 2015-03-25 | 2015-03-25 | |
US62/138058 | 2015-03-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/547,139 A-371-Of-International US20180015079A1 (en) | 2015-03-25 | 2016-03-23 | Therapeutic agent for bile duct cancer |
US16/225,772 Continuation US20190111043A1 (en) | 2015-03-25 | 2018-12-19 | Therapeutic agent for bile duct cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016152907A1 true WO2016152907A1 (ja) | 2016-09-29 |
Family
ID=56979199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/059162 WO2016152907A1 (ja) | 2015-03-25 | 2016-03-23 | 胆管癌治療剤 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20180015079A1 (ja) |
EP (1) | EP3275442B1 (ja) |
JP (1) | JP6503450B2 (ja) |
KR (1) | KR102537152B1 (ja) |
CN (2) | CN114984013A (ja) |
AU (1) | AU2016237222B2 (ja) |
BR (1) | BR112017016392B1 (ja) |
CA (1) | CA2974937C (ja) |
ES (1) | ES2887148T3 (ja) |
IL (1) | IL253701B (ja) |
MX (1) | MX2017009892A (ja) |
RU (1) | RU2712222C2 (ja) |
SG (1) | SG11201706143SA (ja) |
WO (1) | WO2016152907A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019073998A1 (en) * | 2017-10-12 | 2019-04-18 | Eisai R&D Management Co., Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING A TYPICAL KINASE FGFR SELECTIVE INHIBITOR |
US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201706143SA (en) * | 2015-03-25 | 2017-09-28 | Nat Cancer Ct | Therapeutic agent for bile duct cancer |
KR102216430B1 (ko) | 2018-07-19 | 2021-02-17 | 주식회사 엘지화학 | 다환 화합물 및 이를 포함하는 유기 발광 소자 |
KR102297723B1 (ko) | 2018-08-07 | 2021-09-02 | 주식회사 엘지화학 | 다환 화합물 및 이를 포함하는 유기 발광 소자 |
AU2019342289A1 (en) * | 2018-09-21 | 2021-03-18 | Janssen Pharmaceutica Nv | Treatment of cholangiocarcinoma |
KR102239440B1 (ko) | 2019-07-31 | 2021-04-13 | 주식회사 엘지화학 | 다환 화합물 및 이를 포함하는 유기 발광 소자 |
CN115298185A (zh) | 2020-04-16 | 2022-11-04 | 株式会社Lg化学 | 杂环化合物和包含其的有机发光元件 |
WO2021210636A1 (ja) | 2020-04-17 | 2021-10-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
KR102565720B1 (ko) | 2020-06-12 | 2023-08-11 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
KR20220009674A (ko) | 2020-07-16 | 2022-01-25 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
US20230172924A1 (en) | 2020-07-31 | 2023-06-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
WO2022092085A1 (ja) | 2020-10-28 | 2022-05-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
KR20220074408A (ko) | 2020-11-27 | 2022-06-03 | 주식회사 엘지화학 | 다환 화합물 및 이를 포함하는 유기 발광 소자 |
KR20220081059A (ko) | 2020-12-08 | 2022-06-15 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
KR20220081057A (ko) | 2020-12-08 | 2022-06-15 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20220081944A (ko) | 2020-12-09 | 2022-06-16 | 주식회사 엘지화학 | 유기 발광 소자 |
KR20220081941A (ko) | 2020-12-09 | 2022-06-16 | 주식회사 엘지화학 | 유기 발광 소자 |
KR20220081942A (ko) | 2020-12-09 | 2022-06-16 | 주식회사 엘지화학 | 유기 발광 소자 |
KR20220081943A (ko) | 2020-12-09 | 2022-06-16 | 주식회사 엘지화학 | 유기발광소자 |
KR102639498B1 (ko) | 2020-12-24 | 2024-02-22 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
KR20220119318A (ko) | 2021-02-19 | 2022-08-29 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
CN116685587A (zh) | 2021-02-19 | 2023-09-01 | 株式会社Lg化学 | 化合物及包含其的有机发光器件 |
KR20220163287A (ko) | 2021-06-02 | 2022-12-09 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230013405A (ko) | 2021-07-19 | 2023-01-26 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230018103A (ko) | 2021-07-29 | 2023-02-07 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230028184A (ko) | 2021-08-20 | 2023-02-28 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230028185A (ko) | 2021-08-20 | 2023-02-28 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230028183A (ko) | 2021-08-20 | 2023-02-28 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230032260A (ko) | 2021-08-30 | 2023-03-07 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230038348A (ko) | 2021-09-10 | 2023-03-20 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
CN117177978A (zh) | 2021-11-12 | 2023-12-05 | 株式会社Lg化学 | 化合物及包含其的有机发光器件 |
KR20230093174A (ko) | 2021-12-17 | 2023-06-27 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230096689A (ko) | 2021-12-23 | 2023-06-30 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230096688A (ko) | 2021-12-23 | 2023-06-30 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230096691A (ko) | 2021-12-23 | 2023-06-30 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230108721A (ko) | 2022-01-11 | 2023-07-18 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230108393A (ko) | 2022-01-11 | 2023-07-18 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230108720A (ko) | 2022-01-11 | 2023-07-18 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230108395A (ko) | 2022-01-11 | 2023-07-18 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
WO2023136476A1 (ko) | 2022-01-13 | 2023-07-20 | 주식회사 엘지화학 | 다환 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230134849A (ko) | 2022-03-15 | 2023-09-22 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230134848A (ko) | 2022-03-15 | 2023-09-22 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
WO2023177176A1 (ko) | 2022-03-15 | 2023-09-21 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230134847A (ko) | 2022-03-15 | 2023-09-22 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230138209A (ko) | 2022-03-23 | 2023-10-05 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230138211A (ko) | 2022-03-23 | 2023-10-05 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230147550A (ko) | 2022-04-14 | 2023-10-23 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20230152477A (ko) | 2022-04-27 | 2023-11-03 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
CN117940423A (zh) | 2022-06-03 | 2024-04-26 | 株式会社Lg化学 | 化合物及包含其的有机发光器件 |
WO2023244000A1 (ko) | 2022-06-15 | 2023-12-21 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
WO2024005486A1 (ko) | 2022-06-27 | 2024-01-04 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20240041613A (ko) | 2022-09-23 | 2024-04-01 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20240041847A (ko) | 2022-09-23 | 2024-04-01 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
KR20240041846A (ko) | 2022-09-23 | 2024-04-01 | 주식회사 엘지화학 | 화합물 및 이를 포함하는 유기 발광 소자 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014007369A1 (ja) * | 2012-07-05 | 2014-01-09 | 独立行政法人国立がん研究センター | Fgfr2融合遺伝子 |
JP2014237707A (ja) * | 2013-02-20 | 2014-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 単環ピリジン誘導体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2489408B (en) * | 2011-03-23 | 2015-08-05 | Techtronic Floor Care Tech Ltd | Suction cleaner |
US9750741B2 (en) * | 2013-03-15 | 2017-09-05 | The Translational Genomics Research Institute | Targeted therapies for cancer |
SG11201706143SA (en) * | 2015-03-25 | 2017-09-28 | Nat Cancer Ct | Therapeutic agent for bile duct cancer |
-
2016
- 2016-03-23 SG SG11201706143SA patent/SG11201706143SA/en unknown
- 2016-03-23 WO PCT/JP2016/059162 patent/WO2016152907A1/ja active Application Filing
- 2016-03-23 CN CN202210570963.XA patent/CN114984013A/zh active Pending
- 2016-03-23 RU RU2017127135A patent/RU2712222C2/ru active
- 2016-03-23 KR KR1020177021185A patent/KR102537152B1/ko active IP Right Grant
- 2016-03-23 ES ES16768810T patent/ES2887148T3/es active Active
- 2016-03-23 CA CA2974937A patent/CA2974937C/en active Active
- 2016-03-23 BR BR112017016392-6A patent/BR112017016392B1/pt active IP Right Grant
- 2016-03-23 CN CN201680007472.7A patent/CN107205996A/zh active Pending
- 2016-03-23 US US15/547,139 patent/US20180015079A1/en active Pending
- 2016-03-23 JP JP2017508383A patent/JP6503450B2/ja active Active
- 2016-03-23 EP EP16768810.0A patent/EP3275442B1/en active Active
- 2016-03-23 AU AU2016237222A patent/AU2016237222B2/en active Active
- 2016-03-23 MX MX2017009892A patent/MX2017009892A/es unknown
-
2017
- 2017-07-27 IL IL253701A patent/IL253701B/en active IP Right Grant
-
2018
- 2018-12-19 US US16/225,772 patent/US20190111043A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014007369A1 (ja) * | 2012-07-05 | 2014-01-09 | 独立行政法人国立がん研究センター | Fgfr2融合遺伝子 |
JP2014237707A (ja) * | 2013-02-20 | 2014-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 単環ピリジン誘導体 |
Non-Patent Citations (3)
Title |
---|
ARAI, YASUHITO ET AL.: "Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma", HEPATOLOGY, vol. 59, no. 4, 2014, pages 1427 - 1434, XP055215548, ISSN: 0270-9139 * |
BORAD J.MITESH ET AL.: "Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma", PLOS GENETICS, vol. 10, no. 2, e1004135, 2014, pages 1 - 21, XP055317613, ISSN: 1553-7390 * |
TATSUHIRO SHIBATA: "Tankan Gan ni Okeru FGFR2 Yugo Idenshi Hatsugen no Rinshoteki Igi", THE BILIARY TRACT & PANCREAS, vol. 36, no. 2, 12 February 2015 (2015-02-12), pages 137 - 142, XP009506214, ISBN: 978-4-86517-154-9 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019073998A1 (en) * | 2017-10-12 | 2019-04-18 | Eisai R&D Management Co., Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING A TYPICAL KINASE FGFR SELECTIVE INHIBITOR |
JP2020536846A (ja) * | 2017-10-12 | 2020-12-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Fgfr選択的チロシンキナーゼ阻害剤を含む医薬組成物 |
US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
Also Published As
Publication number | Publication date |
---|---|
EP3275442A4 (en) | 2018-09-19 |
AU2016237222A1 (en) | 2017-08-17 |
US20190111043A1 (en) | 2019-04-18 |
CN114984013A (zh) | 2022-09-02 |
BR112017016392B1 (pt) | 2023-02-23 |
EP3275442B1 (en) | 2021-07-28 |
US20180015079A1 (en) | 2018-01-18 |
CA2974937C (en) | 2023-09-05 |
ES2887148T3 (es) | 2021-12-21 |
AU2016237222B2 (en) | 2021-04-29 |
MX2017009892A (es) | 2017-11-15 |
JP6503450B2 (ja) | 2019-04-17 |
CA2974937A1 (en) | 2016-09-29 |
IL253701A0 (en) | 2017-09-28 |
SG11201706143SA (en) | 2017-09-28 |
JPWO2016152907A1 (ja) | 2018-01-18 |
KR102537152B1 (ko) | 2023-05-26 |
CN107205996A (zh) | 2017-09-26 |
EP3275442A1 (en) | 2018-01-31 |
BR112017016392A2 (ja) | 2018-03-27 |
KR20170126443A (ko) | 2017-11-17 |
IL253701B (en) | 2021-01-31 |
RU2017127135A3 (ja) | 2019-08-22 |
RU2712222C2 (ru) | 2020-01-27 |
RU2017127135A (ru) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016152907A1 (ja) | 胆管癌治療剤 | |
KR102575246B1 (ko) | 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물 | |
JP6708849B1 (ja) | ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物 | |
US9573899B2 (en) | USP7 inhibitor compounds and methods of use | |
JP2021165270A (ja) | 置換アリールエーテル系化合物、その調製方法、医薬組成物およびその応用 | |
KR20180094862A (ko) | 유방암 치료제 | |
WO2007121662A1 (fr) | Dérivés de diphénylurée utilisés comme inhibiteurs de kinase, compositions et utilisations de ceux-ci | |
JP2021529175A (ja) | Cdk4/6活性阻害化合物の結晶形およびその使用 | |
WO2015182625A1 (ja) | Ras活性阻害薬及びその用途 | |
CN113444074B (zh) | 一种具有EGFR和Wnt双重抑制作用的化合物及其制备方法和应用 | |
WO2014086102A1 (zh) | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 | |
CN111362871B (zh) | 取代的吡啶-2-甲酰胺类化合物及其用途 | |
US20200276181A1 (en) | Thienoisoquinolines and their derivatives for targeting tubulin, ch-tog, aurora a kinase, tpx2, cdk5rap2 and/or aspm | |
CN113135938B (zh) | 取代的大环类酪氨酸激酶抑制剂及其用途 | |
TWI725041B (zh) | 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 | |
JP2010031001A (ja) | 複素環化合物、その製造法および用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16768810 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017508383 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2974937 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 253701 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 20177021185 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2016768810 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15547139 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/009892 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201706143S Country of ref document: SG |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017016392 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2016237222 Country of ref document: AU Date of ref document: 20160323 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017127135 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 112017016392 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170731 |